Edgar Stanley, MD
Family Medicine · Palm Springs, CANPI 1184688624
Payments from drug & device makers
Across 332 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$872
- Amgen$726
- AstraZeneca$647
- Merck$422
- GSK$379
- Pfizer$321
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 47 | $872 |
| Amgen | 28 | $726 |
| AstraZeneca | 35 | $647 |
| Merck | 20 | $422 |
| GSK | 22 | $379 |
| Pfizer | 16 | $321 |
| Lilly USA, LLC | 15 | $304 |
| Boehringer Ingelheim | 12 | $283 |
| Kowa Pharmaceuticals America, Inc. | 14 | $251 |
| Amarin Pharma, Inc. | 16 | $251 |
| Viiv Healthcare Company | 12 | $240 |
| Boston Scientific | 4 | $197 |
| AbbVie | 10 | $193 |
| Novo Nordisk | 11 | $191 |
| Novartis | 11 | $183 |
| Esperion Therapeutics, Inc. | 8 | $169 |
| Abbott | 7 | $156 |
| Intuitive Surgical | 2 | $153 |
| Johnson & Johnson(2 entities) | 6 | $139 |
| Phathom Pharmaceuticals, Inc. | 5 | $120 |
| Seqirus USA Inc | 4 | $88 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Sanofi Pasteur Inc. | 4 | $80 |
| Astellas Pharma US Inc | 3 | $78 |
| ERBE USA Inc | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Hologic Sales And Service, LLC | 2 | $27 |
| Si-bone, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Edwards Lifesciences | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$244
- WATCHMAN Access System$135
- Da Vinci Surgical System$119
- STEGLATRO$106
How this compares
$6,837 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 236 | $263,416 |
| EliquisApixaban | 152 | $182,081 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 40 | $164,564 |
| JardianceEmpagliflozin | 68 | $108,766 |
| DescovyEmtricitabine/Tenofov Alafenam | 38 | $98,252 |
| TrulicityDulaglutide | 61 | $89,909 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 21 | $86,264 |
| XareltoRivaroxaban | 47 | $70,465 |
| MounjaroTirzepatide | 53 | $69,937 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $64,658 |
| JanuviaSitagliptin Phosphate | 33 | $47,483 |
| RybelsusSemaglutide | 14 | $35,995 |
| FarxigaDapagliflozin Propanediol | 35 | $28,603 |
| RexultiBrexpiprazole | 14 | $23,838 |
| Repatha SureclickEvolocumab | 29 | $23,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $872 | $327,47492 claims |
| Novo NordiskOzempic, Rybelsus | $191 | $299,411250 claims |
| PfizerEliquis | $321 | $182,081152 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $304 | $167,914125 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $283 | $142,180111 claims |
| Johnson & JohnsonXarelto | $139 | $70,46547 claims |
| MerckJanuvia | $422 | $47,48333 claims |
| AstraZenecaFarxiga, Symbicort | $647 | $36,15657 claims |
| GSKBreo Ellipta, Anoro Ellipta | $379 | $24,72539 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $12 | $24,15149 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $42 | $23,83814 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $11,12211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Palm Springs
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.